{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:57Z","timestamp":1788556437937,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020555","name":"Intas Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012618","name":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201756","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:01:40Z","timestamp":1778310100000},"page":"201756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4300-2033","authenticated-orcid":false,"given":"Ahmed","family":"Salman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaluddeen","family":"Garba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah A.","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Szczepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charnitkaur B.","family":"Jashal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajanathan","family":"Chozhavel T M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kush","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Ming","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-4305","authenticated-orcid":false,"given":"Andrew J.","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201756_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.omta.2026.201756_bib2","first-page":"493","article-title":"Updates on the Epidemiology of Age-Related Macular Degeneration","volume":"6","author":"Jonas","year":"2017","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib3","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ophtha.2015.08.002","article-title":"The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study","volume":"122","author":"Joachim","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2022.6381","article-title":"Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"327","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.omta.2026.201756_bib5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.survophthal.2023.02.004","article-title":"Practical guidance for imaging biomarkers in exudative age-related macular degeneration","volume":"68","author":"Rispoli","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40123-020-00291-5","article-title":"Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration","volume":"9","author":"Karampelas","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.omta.2026.201756_bib8","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1038\/s41598-022-08492-7","article-title":"Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients","volume":"12","author":"Shahidatul-Adha","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201756_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201756_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41433-024-03373-x","article-title":"Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues","volume":"39","author":"Shirian","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.omta.2026.201756_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","volume":"120","author":"Miller","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/ceo.13834","article-title":"Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms","volume":"48","author":"Somasundaran","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration","volume":"22","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.omta.2026.201756_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0161-6420(03)00085-X","article-title":"Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101323","article-title":"Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration","volume":"104","author":"Corydon","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omta.2026.201756_bib17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201756_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ajo.2024.12.002","article-title":"Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases","volume":"277","author":"Khanani","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1089\/hum.2011.090","article-title":"Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab","volume":"22","author":"Mao","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201756_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2022.130764","article-title":"VEGF-targeted scFv inhibits corneal neovascularization via STAT3 pathway in alkali burn model","volume":"658","author":"Cui","year":"2023","journal-title":"Colloids Surf."},{"key":"10.1016\/j.omta.2026.201756_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101145","article-title":"AAV2-antiVEGFscFv gene therapy for retinal neovascularization","volume":"31","author":"Han","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201756_bib22","first-page":"23","volume":"62","year":"2020","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.omta.2026.201756_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41433-019-0582-0","article-title":"Brolucizumab: is extended VEGF suppression on the horizon?","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.omta.2026.201756_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/aes-21-41","article-title":"Molecular structure, pharmacokinetics and clinical evidence of brolucizumab: a narrative review","volume":"6","author":"Pignatelli","year":"2021","journal-title":"Ann. Eye Sci."},{"key":"10.1016\/j.omta.2026.201756_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201756_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201756_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/gt.2011.3","article-title":"AAV-mediated photoreceptor transduction of the pig cone-enriched retina","volume":"18","author":"Mussolino","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201756_bib30","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/hum.2020.043","article-title":"Retinal Tropism and Transduction of Adeno-Associated Virus Varies by Serotype and Route of Delivery (Intravitreal, Subretinal, or Suprachoroidal) in Rats","volume":"31","author":"Han","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201756_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041580","article-title":"Tropism of the AAV6.2 Vector in the Murine Retina","volume":"26","author":"Suzuki","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201756_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201756_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11092445","article-title":"Neovascular Progression and Retinal Dysfunction in the Laser-Induced Choroidal Neovascularization Mouse Model","volume":"11","author":"Salas","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omta.2026.201756_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028933","article-title":"Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344","volume":"6","author":"Xie","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201756_bib36","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1111\/jcmm.17562","article-title":"Delayed regression of laser-induced choroidal neovascularization in TNFalpha-null mice","volume":"26","author":"Iwanishi","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.omta.2026.201756_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.9.4.3","article-title":"A Two-Stage Laser-Induced Mouse Model of Subretinal Fibrosis Secondary to Choroidal Neovascularization","volume":"9","author":"Little","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.omta.2026.201756_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(99)00285-6","article-title":"Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys","volume":"732","author":"Tucker","year":"1999","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.omta.2026.201756_bib39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"Drolet","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omta.2026.201756_bib40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1742-1241.2007.01299.x","article-title":"Ranibizumab for the treatment of neovascular AMD","volume":"61","author":"Kaiser","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.omta.2026.201756_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Arnold","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201756_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1006\/exer.2000.0907","article-title":"Quantitative image analysis of laser-induced choroidal neovascularization in rat","volume":"71","author":"Edelman","year":"2000","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omta.2026.201756_bib44","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1167\/iovs.10-6266","article-title":"In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography","volume":"52","author":"Giani","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omta.2026.201756_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omtn.2019.01.012","article-title":"Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy","volume":"16","author":"Askou","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omta.2026.201756_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101242","article-title":"Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model","volume":"32","author":"Haldrup","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201756_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107939","article-title":"Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration","volume":"26","author":"Wei-Zhang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.omta.2026.201756_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102833","article-title":"AAV-mediated multiple gene therapy combining VEGFA-targeting miR-agshRNAs and PEDF for the suppression of choroidal neovascularization","volume":"37","author":"Fabian-Jessing","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omta.2026.201756_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/iovs.64.13.16","article-title":"Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography","volume":"64","author":"Shen","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omta.2026.201756_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1411278","article-title":"Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications","volume":"11","author":"Cheng","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.omta.2026.201756_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111629","article-title":"Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.omta.2026.201756_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0014-5793(01)03101-5","article-title":"Antigen-independent selection of stable intracellular single-chain antibodies","volume":"508","author":"Auf der Maur","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omta.2026.201756_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2249.2002.01808.x","article-title":"Penetration of engineered antibody fragments into the eye","volume":"128","author":"Thiel","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omta.2026.201756_bib54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41433-020-01351-7","article-title":"Correction: Brolucizumab-early real-world experience: BREW study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.omta.2026.201756_bib55","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2147\/OPTH.S425709","article-title":"Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis","volume":"17","author":"Saba","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201756_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omta.2026.201756_bib57","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.76.15.7651-7660.2002","article-title":"Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size","volume":"76","author":"Yang","year":"2002","journal-title":"J. Virol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:30:27Z","timestamp":1788553827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000911"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201756","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201756"}}